TOPICAL COMPOSITION COMPRISING TRANSFORMED BACTERIA EXPRESSING A COMPOUND OF INTEREST

• US 20140044677A1
• Filed: 08/07/2013
• Published: 02/13/2014
• Est. Priority Date: 08/07/2012
• Status: Active Grant

• Current Assignee: TopGeniX Inc.
• Original Assignee: TopGeniX Inc.
• Inventors: Qvit-Raz, Noga, Altman, Tahel
• Granted Patent: US 9,868,957 B2
• Time in Patent Office: Days
• US Class Current: 424/93.2
• CPC Class Codes: A61K 2800/592 Mixtures of compounds complementing their respective functions
• CPC Class Codes: A61K 35/744 Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
• CPC Class Codes: A61K 8/27 Zinc; Compounds thereof
• CPC Class Codes: A61K 8/40 containing nitrogen quinones containing nitrogen A61K8/355
• CPC Class Codes: A61K 8/99 from microorganisms other than algae or fungi, e.g. protozoa or bacteria
• CPC Class Codes: A61P 17/00 Drugs for dermatological disorders
• CPC Class Codes: A61P 17/06 Antipsoriatics
• CPC Class Codes: A61P 17/16 Emollients or protectives, e.g. against radiation
• CPC Class Codes: A61P 17/18 Antioxidants, e.g. antiradicals preparations for protection against sunlight A61Q17/00
• CPC Class Codes: A61P 39/06 Free radical scavengers or antioxidants
• CPC Class Codes: A61Q 17/00 Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
• CPC Class Codes: A61Q 17/04 Topical preparations for affording protection against sunlight or other radiation; Topical sun tanning preparations
• CPC Class Codes: A61Q 19/007 Preparations for dry skin
• CPC Class Codes: A61Q 19/08 Anti-ageing preparations
• CPC Class Codes: C12N 15/746 for lactic acid bacteria (Streptococcus; Lactococcus; Lactobacillus; Pediococcus; Enterococcus; Leuconostoc; Propionibacterium; Bifidobacterium; Sporolactobacillus)

Abstract

Compositions comprised of a population of transformed bacteria formulated for topical application to a subject are described. The population of transformed bacteria are created from a non-pathogenic bacteria and transformed to express a compound of interest for a therapeutic or a cosmetic purpose. In one embodiment, the composition is for protection of the skin from ultraviolet rays.

Claims

1. A composition, comprising:

a population of non-pathogenic bacteria transformed to express a compound of interest, the composition formulated for topical application to a subject.

2. The composition of claim 1, wherein the population of non-pathogenic bacteria is a population of live bacteria that express the compound of interest.

3. The composition of claim 2, wherein the population of non-pathogenic bacteria is attenuated bacteria or killed bacteria that express the compound of interest prior to or after attenuation or prior to killing.

4. The composition of claim 3, wherein the population of non-pathogenic bacteria comprises fragments of the transformed, non-pathogenic bacteria.

5. The composition of claim 1, wherein the compound of interest is one for treating psoriasis.

6. The composition of claim 5, wherein the compound is selected from the group consisting of Retinoid, Vitamin A, derivatives of Vitamin A, beta-carotene, Vitamin D, derivatives of Vitamin D, anti-inflammatory cytokines.

7. The composition of claim 1, wherein the compound of interest is an anti-oxidant.

8. The composition of claim 7, wherein the compound is selected from the group consisting of resveratrol, vitamin E, vitamin C, -epigallocatechin-3-gallate, and retinyl palmitate (retinoids), lutein, tamarind, flavonoids, pycnogenol, lycopene.

9. The composition of claim 1, wherein the compound of interest provides a cosmetic effect.

10. The composition of claim 9, wherein the compound is selected from the group consisting of coenzyme Q10, tyrosinases, collagen, laminin, ceramids, linoleic acid, tretinoin, tazarotene and collagen.

11. The composition of claim 10, wherein the cosmetic effect is anti-aging or moisturizing

12. The composition of claim 1, wherein the compound of interest is one that treats eczema.

13. The composition of claim 12, wherein the compound is selected from the group consisting of cortisone, tacrolimus and ciclosporin.

14. The composition of claim 1, wherein the population of transformed bacteria is created from a population of non-pathogenic bacteria resident on the skin in humans.

15. The composition of claim 1, wherein the population of transformed bacteria is created from nonpathogenic bacterial members selected from those in the group consisting of Acinetobacter, Actinomycetales, Anaerococcus, Bacillales, Bifidobacterium, Enhydrobacter, Enterococcus, Finegoldia, Carnobacterium, Coryneobacterium, Lactobacillus, Lactococcus, Leunconostoc, Macrooccus, Micrococcineae, Oenococcus, Pediococcus, Peptoniphilus, Propionibacterium, Salinicoccus, Sphingomonas, Strepococcus, Tetragenoccus, and Weissella.

16. The composition claim 1, wherein the population of transformed bacteria is created from a bacteria selected from those in the group consisting of Lactobacillus casei, Lactobacillus reuteri, Lactobacillus acidophilus, Lactobacillus jensenii, Bifidobacterium lognum, Bifidobacterium reuteri, Bifidobacterium lactis, Bifidobacterium breve, Bifidobacterium animalis, Propionibacterium acidipropionici, Propionibacterium freudenreichii, Propionibacterium thoenii, and Propionibacterium jensenii.

17. The composition of claim 1, wherein the population of transformed nonpathogenic bacterial members is created from those in a phylum selected from the group consisting of gamma-proteobacteria, alpha-proteobacteria, and bacteriodetes.

18. A method of treatment, comprising:

topically administering a composition according to claim 1.

19. A method for delivering a compound to the skin for a therapeutic or cosmetic purpose, comprising:

applying to the skin a composition comprising a population of a non-pathogenic bacteria transformed to express the compound of interest, the population of bacteria comprised of a bacterial strain in the skin microbiome.

20. A composition, comprising:

a population of non-pathogenic bacteria from the skin microbiome, at least a portion of the population of bacteria transformed to express a compound of interest, the composition formulated for topical application to a subject.